|  Help  |  About  |  Contact Us

Search our database by keyword

- or -

Examples

  • Search this entire website. Enter identifiers, names or keywords for genes, diseases, strains, ontology terms, etc. (e.g. Pax6, Parkinson, ataxia)
  • Use OR to search for either of two terms (e.g. OR mus) or quotation marks to search for phrases (e.g. "dna binding").
  • Boolean search syntax is supported: e.g. Balb* for partial matches or mus AND NOT embryo to exclude a term

Search results 2101 to 2200 out of 2570 for Kras

Category restricted to Publication (x)

<< First    < Previous  |  Next >    Last >>
0.057s

Categories

Category: Publication
« show all
Type Details Score
Publication
15894260 | J:98833
First Author: Siveke JT
Year: 2005
Journal: Cancer Cell
Title: Chromosomal instability in mouse metastatic pancreatic cancer--it's Kras and Tp53 after all.
Volume: 7
Issue: 5
Pages: 405-7
•
•
•
•
•
Publication
31521603 | J:349043
First Author: Brubaker DK
Year: 2019
Journal: Cell Syst
Title: Proteogenomic Network Analysis of Context-Specific KRAS Signaling in Mouse-to-Human Cross-Species Translation.
Volume: 9
Issue: 3
Pages: 258-270.e6
•
•
•
•
•
Publication
29263151 | J:253861
First Author: Dias Carvalho P
Year: 2018
Journal: Cancer Res
Title: KRAS Oncogenic Signaling Extends beyond Cancer Cells to Orchestrate the Microenvironment.
Volume: 78
Issue: 1
Pages: 7-14
•
•
•
•
•
Publication
33082413 | J:298994
First Author: Ryu HH
Year: 2020
Journal: Sci Rep
Title: Neuron type-specific expression of a mutant KRAS impairs hippocampal-dependent learning and memory.
Volume: 10
Issue: 1
Pages: 17730
•
•
•
•
•
Publication
31461438 | J:279455
First Author: Gao W
Year: 2019
Journal: PLoS Biol
Title: Targeting oxidative pentose phosphate pathway prevents recurrence in mutant Kras colorectal carcinomas.
Volume: 17
Issue: 8
Pages: e3000425
•
•
•
•
•
Publication
31646336 | J:296247
First Author: O'Brien G
Year: 2020
Journal: Carcinogenesis
Title: Kras mutations and PU.1 promoter methylation are new pathways in murine radiation-induced AML.
Volume: 41
Issue: 8
Pages: 1104-1112
•
•
•
•
•
Publication
34857889 | J:321217
First Author: Alhayyani S
Year: 2022
Journal: Oncogene
Title: Oncogenic dependency on STAT3 serine phosphorylation in KRAS mutant lung cancer.
Volume: 41
Issue: 6
Pages: 809-823
•
•
•
•
•
Publication
29321164 | J:258681
First Author: Fujimura K
Year: 2018
Journal: Cancer Res
Title: KRAS Oncoprotein Expression Is Regulated by a Self-Governing eIF5A-PEAK1 Feed-Forward Regulatory Loop.
Volume: 78
Issue: 6
Pages: 1444-1456
•
•
•
•
•
Publication
36451866 | J:331710
First Author: Luo YD
Year: 2022
Journal: Theranostics
Title: Mutant Kras and mTOR crosstalk drives hepatocellular carcinoma development via PEG3/STAT3/BEX2 signaling.
Volume: 12
Issue: 18
Pages: 7903-7919
•
•
•
•
•
Publication
24576621 | J:210526
First Author: Roper J
Year: 2014
Journal: Cancer Lett
Title: Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer.
Volume: 347
Issue: 2
Pages: 204-11
•
•
•
•
•
Publication
30995478 | J:288496
First Author: Choi H
Year: 2019
Journal: Cell Rep
Title: Pulsatile MEK Inhibition Improves Anti-tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer.
Volume: 27
Issue: 3
Pages: 806-819.e5
•
•
•
•
•
Publication
28320962 | J:242037
First Author: Mou H
Year: 2017
Journal: Proc Natl Acad Sci U S A
Title: Genetic disruption of oncogenic Kras sensitizes lung cancer cells to Fas receptor-mediated apoptosis.
Volume: 114
Issue: 14
Pages: 3648-3653
•
•
•
•
•
Publication
30104206 | J:266078
First Author: Mackedenski S
Year: 2018
Journal: Biochem J
Title: Characterizing the interaction between insulin-like growth factor 2 mRNA-binding protein 1 (IMP1) and KRAS expression.
Volume: 475
Issue: 17
Pages: 2749-2767
•
•
•
•
•
Publication
37277019 | J:336651
 
First Author: Liu ZY
Year: 2023
Journal: Cancer Lett
Title: FBXW10-S6K1 promotes ANXA2 polyubiquitination and KRAS activation to drive hepatocellular carcinoma development in males.
Volume: 566
Pages: 216257
•
•
•
•
•
Publication
38975873 | J:357840
First Author: Singhal A
Year: 2024
Journal: Cancer Discov
Title: A Classical Epithelial State Drives Acute Resistance to KRAS Inhibition in Pancreatic Cancer.
Volume: 14
Issue: 11
Pages: 2122-2134
•
•
•
•
•
Publication
37067057 | J:335421
First Author: Tomoshige K
Year: 2023
Journal: Cancer Res
Title: FOXA2 Cooperates with Mutant KRAS to Drive Invasive Mucinous Adenocarcinoma of the Lung.
Volume: 83
Issue: 9
Pages: 1443-1458
•
•
•
•
•
Publication
31390566 | J:288429
First Author: Campbell KM
Year: 2019
Journal: Cell Rep
Title: A Spontaneous Aggressive ERα+ Mammary Tumor Model Is Driven by Kras Activation.
Volume: 28
Issue: 6
Pages: 1526-1537.e4
•
•
•
•
•
Publication
- | J:311938
     
First Author: de Carne Trecesson S
Year: 2020
Journal: bioRxiv
Title: APOBEC3B expression generates an immunogenetic model of Kras mutant lung cancer.
•
•
•
•
•
Publication
26047463 | J:223771
 
First Author: Unni AM
Year: 2015
Journal: Elife
Title: Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma.
Volume: 4
Pages: e06907
•
•
•
•
•
Publication
30853214 | J:275999
First Author: Hu CM
Year: 2019
Journal: Cell Metab
Title: High Glucose Triggers Nucleotide Imbalance through O-GlcNAcylation of Key Enzymes and Induces KRAS Mutation in Pancreatic Cells.
Volume: 29
Issue: 6
Pages: 1334-1349.e10
•
•
•
•
•
Publication
39232498 | J:361502
First Author: Yang D
Year: 2024
Journal: Cell Rep Med
Title: Loss of p53 and SMAD4 induces adenosquamous subtype pancreatic cancer in the absence of an oncogenic KRAS mutation.
Volume: 5
Issue: 9
Pages: 101711
•
•
•
•
•
Publication
36693323 | J:333004
First Author: Chatzeli L
Year: 2023
Journal: Dev Cell
Title: A cellular hierarchy of Notch and Kras signaling controls cell fate specification in the developing mouse salivary gland.
Volume: 58
Issue: 2
Pages: 94-109.e6
•
•
•
•
•
Publication
8859779 | J:40417
First Author: Chiappetta G
Year: 1996
Journal: Oncol Res
Title: Transgenic mice carrying the human KRAS oncogene under the control of a thyroglobulin promoter: KRAS expression in thyroids analyzed by in situ hybridization.
Volume: 8
Issue: 2
Pages: 85-93
•
•
•
•
•
Publication
35247892 | J:324782
First Author: Nagao M
Year: 2022
Journal: Cancer Res
Title: Concurrent Activation of Kras and Canonical Wnt Signaling Induces Premalignant Lesions That Progress to Extrahepatic Biliary Cancer in Mice.
Volume: 82
Issue: 9
Pages: 1803-1817
•
•
•
•
•
Publication
17510423 | J:121738
First Author: Ji H
Year: 2007
Journal: Cancer Res
Title: Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models.
Volume: 67
Issue: 10
Pages: 4933-9
•
•
•
•
•
Publication
29844447 | J:263205
First Author: Weng TY
Year: 2018
Journal: Sci Rep
Title: Homoharringtonine induced immune alteration for an Efficient Anti-tumor Response in Mouse Models of Non-small Cell Lung Adenocarcinoma Expressing Kras Mutation.
Volume: 8
Issue: 1
Pages: 8216
•
•
•
•
•
Publication
19609923 | J:157052
First Author: Dwyer-Nield LD
Year: 2010
Journal: Int J Cancer
Title: Epistatic interactions govern chemically-induced lung tumor susceptibility and Kras mutation site in murine C57BL/6J-ChrA/J chromosome substitution strains.
Volume: 126
Issue: 1
Pages: 125-32
•
•
•
•
•
Publication
39412982 | J:361617
First Author: Fey SK
Year: 2025
Journal: Cancer Res
Title: KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition.
Volume: 85
Issue: 2
Pages: 251-262
•
•
•
•
•
Publication
29912950 | J:263352
First Author: Dompe N
Year: 2018
Journal: PLoS One
Title: A CRISPR screen identifies MAPK7 as a target for combination with MEK inhibition in KRAS mutant NSCLC.
Volume: 13
Issue: 6
Pages: e0199264
•
•
•
•
•
Publication
30353028 | J:268435
First Author: Mohamed AD
Year: 2018
Journal: Sci Rep
Title: Analysis of the relationship between the KRAS G12V oncogene and the Hippo effector YAP1 in embryonal rhabdomyosarcoma.
Volume: 8
Issue: 1
Pages: 15674
•
•
•
•
•
Publication
26173780 | J:320864
 
First Author: Chakrabarti G
Year: 2015
Journal: Radiat Oncol
Title: Mutant KRAS associated malic enzyme 1 expression is a predictive marker for radiation therapy response in non-small cell lung cancer.
Volume: 10
Pages: 145
•
•
•
•
•
Publication
28400509 | J:242240
First Author: Gouw AM
Year: 2017
Journal: Proc Natl Acad Sci U S A
Title: Oncogene KRAS activates fatty acid synthase, resulting in specific ERK and lipid signatures associated with lung adenocarcinoma.
Volume: 114
Issue: 17
Pages: 4300-4305
•
•
•
•
•
Publication
12359767 | J:79689
First Author: Uhrbom L
Year: 2002
Journal: Cancer Res
Title: Ink4a-Arf loss cooperates with KRas activation in astrocytes and neural progenitors to generate glioblastomas of various morphologies depending on activated Akt.
Volume: 62
Issue: 19
Pages: 5551-8
•
•
•
•
•
Publication
34769463 | J:314700
 
First Author: Mickler EA
Year: 2021
Journal: Int J Mol Sci
Title: Low-Coverage Whole Genome Sequencing Using Laser Capture Microscopy with Combined Digital Droplet PCR: An Effective Tool to Study Copy Number and Kras Mutations in Early Lung Adenocarcinoma Development.
Volume: 22
Issue: 21
•
•
•
•
•
Publication
22525269 | J:193362
First Author: Hollern DP
Year: 2013
Journal: Oncogene
Title: A mouse model with T58A mutations in Myc reduces the dependence on KRas mutations and has similarities to claudin-low human breast cancer.
Volume: 32
Issue: 10
Pages: 1296-304
•
•
•
•
•
Publication
35646902 | J:324985
 
First Author: Ding L
Year: 2022
Journal: Front Cell Dev Biol
Title: Nuclear GSK-3β and Oncogenic KRas Lead to the Retention of Pancreatic Ductal Progenitor Cells Phenotypically Similar to Those Seen in IPMN.
Volume: 10
Pages: 853003
•
•
•
•
•
Publication
23536778 | J:199528
First Author: König K
Year: 2013
Journal: PLoS One
Title: Loss of the keratin cytoskeleton is not sufficient to induce epithelial mesenchymal transition in a novel KRAS driven sporadic lung cancer mouse model.
Volume: 8
Issue: 3
Pages: e57996
•
•
•
•
•
Publication
31406347 | -
First Author: Nissim S
Year: 2019
Journal: Nat Genet
Title: Mutations in RABL3 alter KRAS prenylation and are associated with hereditary pancreatic cancer.
Volume: 51
Issue: 9
Pages: 1308-1314
•
•
•
•
•
Publication
32719131 | J:293934
First Author: Niitsu Y
Year: 2020
Journal: Proc Natl Acad Sci U S A
Title: A CRAF/glutathione-S-transferase P1 complex sustains autocrine growth of cancers with KRAS and BRAF mutations.
Volume: 117
Issue: 32
Pages: 19435-19445
•
•
•
•
•
Publication
25329316 | J:217430
First Author: Esteve-Puig R
Year: 2014
Journal: PLoS Genet
Title: A mouse model uncovers LKB1 as an UVB-induced DNA damage sensor mediating CDKN1A (p21WAF1/CIP1) degradation.
Volume: 10
Issue: 10
Pages: e1004721
•
•
•
•
•
Publication
18172296 | J:131037
First Author: Gurumurthy S
Year: 2008
Journal: Cancer Res
Title: LKB1 deficiency sensitizes mice to carcinogen-induced tumorigenesis.
Volume: 68
Issue: 1
Pages: 55-63
•
•
•
•
•
Publication
25588837 | J:223226
First Author: Krawchuk D
Year: 2015
Journal: J Cell Sci
Title: Loss of LKB1 leads to impaired epithelial integrity and cell extrusion in the early mouse embryo.
Volume: 128
Issue: 5
Pages: 1011-22
•
•
•
•
•
Publication
25256100 | J:316262
 
First Author: Pooya S
Year: 2014
Journal: Nat Commun
Title: The tumour suppressor LKB1 regulates myelination through mitochondrial metabolism.
Volume: 5
Pages: 4993
•
•
•
•
•
Publication
18245476 | J:131865
First Author: Contreras CM
Year: 2008
Journal: Cancer Res
Title: Loss of Lkb1 provokes highly invasive endometrial adenocarcinomas.
Volume: 68
Issue: 3
Pages: 759-66
•
•
•
•
•
Publication
18311138 | J:134476
First Author: Katajisto P
Year: 2008
Journal: Nat Genet
Title: LKB1 signaling in mesenchymal cells required for suppression of gastrointestinal polyposis.
Volume: 40
Issue: 4
Pages: 455-9
•
•
•
•
•
Publication
19541609 | J:150834
First Author: Shackelford DB
Year: 2009
Journal: Proc Natl Acad Sci U S A
Title: mTOR and HIF-1alpha-mediated tumor metabolism in an LKB1 mouse model of Peutz-Jeghers syndrome.
Volume: 106
Issue: 27
Pages: 11137-42
•
•
•
•
•
Publication
31399545 | J:278719
First Author: Hashimoto S
Year: 2019
Journal: Proc Natl Acad Sci U S A
Title: ARF6 and AMAP1 are major targets of KRAS and TP53 mutations to promote invasion, PD-L1 dynamics, and immune evasion of pancreatic cancer.
Volume: 116
Issue: 35
Pages: 17450-17459
•
•
•
•
•
Publication
24019382 | J:204513
First Author: Trejo CL
Year: 2013
Journal: Cancer Res
Title: Mutationally activated PIK3CA(H1047R) cooperates with BRAF(V600E) to promote lung cancer progression.
Volume: 73
Issue: 21
Pages: 6448-61
•
•
•
•
•
Publication
16397237 | J:105076
First Author: Tuveson DA
Year: 2006
Journal: Cancer Res
Title: Mist1-KrasG12D knock-in mice develop mixed differentiation metastatic exocrine pancreatic carcinoma and hepatocellular carcinoma.
Volume: 66
Issue: 1
Pages: 242-7
•
•
•
•
•
Publication
34610416 | J:314038
 
First Author: Kanagasabai T
Year: 2021
Journal: Cancer Lett
Title: MicroRNA-21 deficiency suppresses prostate cancer progression through downregulation of the IRS1-SREBP-1 signaling pathway.
Volume: 525
Pages: 46-54
•
•
•
•
•
Publication
23454771 | J:196375
First Author: Knight DA
Year: 2013
Journal: J Clin Invest
Title: Host immunity contributes to the anti-melanoma activity of BRAF inhibitors.
Volume: 123
Issue: 3
Pages: 1371-81
•
•
•
•
•
Publication
28202513 | J:242087
First Author: Steinberg SM
Year: 2017
Journal: Cancer Res
Title: Myeloid Cells That Impair Immunotherapy Are Restored in Melanomas with Acquired Resistance to BRAF Inhibitors.
Volume: 77
Issue: 7
Pages: 1599-1610
•
•
•
•
•
Publication
31433989 | J:285688
First Author: Di Mitri D
Year: 2019
Journal: Cell Rep
Title: Re-education of Tumor-Associated Macrophages by CXCR2 Blockade Drives Senescence and Tumor Inhibition in Advanced Prostate Cancer.
Volume: 28
Issue: 8
Pages: 2156-2168.e5
•
•
•
•
•
Publication
36599297 | J:332546
First Author: Tsai CH
Year: 2023
Journal: Cell Metab
Title: Immunoediting instructs tumor metabolic reprogramming to support immune evasion.
Volume: 35
Issue: 1
Pages: 118-133.e7
•
•
•
•
•
Publication
26198641 | J:224447
 
First Author: Pencik J
Year: 2015
Journal: Nat Commun
Title: STAT3 regulated ARF expression suppresses prostate cancer metastasis.
Volume: 6
Pages: 7736
•
•
•
•
•
Publication
30664764 | J:282386
First Author: Cheng WC
Year: 2019
Journal: Nat Immunol
Title: Uncoupling protein 2 reprograms the tumor microenvironment to support the anti-tumor immune cycle.
Volume: 20
Issue: 2
Pages: 206-217
•
•
•
•
•
Publication
26317218 | J:243021
First Author: Filtz EA
Year: 2015
Journal: PLoS One
Title: Rb1 and Pten Co-Deletion in Osteoblast Precursor Cells Causes Rapid Lipoma Formation in Mice.
Volume: 10
Issue: 8
Pages: e0136729
•
•
•
•
•
Publication
24493834 | J:208767
First Author: Trent CM
Year: 2014
Journal: J Lipid Res
Title: Lipoprotein lipase activity is required for cardiac lipid droplet production.
Volume: 55
Issue: 4
Pages: 645-58
•
•
•
•
•
Publication
19443706 | J:148919
First Author: Rodriguez OC
Year: 2009
Journal: Am J Pathol
Title: A reduction in Pten tumor suppressor activity promotes ErbB-2-induced mouse prostate adenocarcinoma formation through the activation of signaling cascades downstream of PDK1.
Volume: 174
Issue: 6
Pages: 2051-60
•
•
•
•
•
Publication
17283127 | J:118219
First Author: Yeager N
Year: 2007
Journal: Cancer Res
Title: Pten loss in the mouse thyroid causes goiter and follicular adenomas: insights into thyroid function and Cowden disease pathogenesis.
Volume: 67
Issue: 3
Pages: 959-66
•
•
•
•
•
Publication
14691534 | J:86212
First Author: Trotman LC
Year: 2003
Journal: PLoS Biol
Title: Pten dose dictates cancer progression in the prostate.
Volume: 1
Issue: 3
Pages: E59
•
•
•
•
•
Publication
29202476 | J:258373
First Author: Ollila S
Year: 2018
Journal: J Clin Invest
Title: Stromal Lkb1 deficiency leads to gastrointestinal tumorigenesis involving the IL-11-JAK/STAT3 pathway.
Volume: 128
Issue: 1
Pages: 402-414
•
•
•
•
•
Publication
20676139 | J:165293
First Author: Antico-Arciuch VG
Year: 2010
Journal: Oncogene
Title: Cross-talk between PI3K and estrogen in the mouse thyroid predisposes to the development of follicular carcinomas with a higher incidence in females.
Volume: 29
Issue: 42
Pages: 5678-86
•
•
•
•
•
Publication
24910389 | J:316436
First Author: Xie Y
Year: 2014
Journal: Mol Oncol
Title: Slug regulates E-cadherin repression via p19Arf in prostate tumorigenesis.
Volume: 8
Issue: 7
Pages: 1355-64
•
•
•
•
•
Publication
27356744 | J:264783
First Author: Xie Y
Year: 2016
Journal: Oncotarget
Title: MMP7 interacts with ARF in nucleus to potentiate tumor microenvironments for prostate cancer progression in vivo.
Volume: 7
Issue: 30
Pages: 47609-47619
•
•
•
•
•
Publication
19690330 | J:260259
First Author: Chen Z
Year: 2009
Journal: Sci Signal
Title: Differential p53-independent outcomes of p19(Arf) loss in oncogenesis.
Volume: 2
Issue: 84
Pages: ra44
•
•
•
•
•
Publication
29185453 | J:255776
First Author: Xie Y
Year: 2017
Journal: Sci Rep
Title: Dysregulation of YAP by ARF Stimulated with Tea-derived Carbon Nanodots.
Volume: 7
Issue: 1
Pages: 16577
•
•
•
•
•
Publication
20237562 | J:158121
First Author: Lin HK
Year: 2010
Journal: Nature
Title: Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence.
Volume: 464
Issue: 7287
Pages: 374-9
•
•
•
•
•
Publication
25995385 | J:225608
First Author: Dorr C
Year: 2015
Journal: Mol Cancer Res
Title: Transposon Mutagenesis Screen Identifies Potential Lung Cancer Drivers and CUL3 as a Tumor Suppressor.
Volume: 13
Issue: 8
Pages: 1238-47
•
•
•
•
•
Publication
20197621 | J:158734
First Author: Alimonti A
Year: 2010
Journal: J Clin Invest
Title: A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis.
Volume: 120
Issue: 3
Pages: 681-93
•
•
•
•
•
Publication
29784854 | J:264280
First Author: Saito R
Year: 2018
Journal: Cancer Res
Title: Molecular Subtype-Specific Immunocompetent Models of High-Grade Urothelial Carcinoma Reveal Differential Neoantigen Expression and Response to Immunotherapy.
Volume: 78
Issue: 14
Pages: 3954-3968
•
•
•
•
•
Publication
31092557 | J:317985
First Author: Nowak DG
Year: 2019
Journal: J Cell Biol
Title: The PHLPP2 phosphatase is a druggable driver of prostate cancer progression.
Volume: 218
Issue: 6
Pages: 1943-1957
•
•
•
•
•
Publication
27728797 | J:236719
First Author: Murray NR
Year: 2016
Journal: Cancer Cell
Title: SOX2 Determines Lineage Restriction: Modeling Lung Squamous Cell Carcinoma in the Mouse.
Volume: 30
Issue: 4
Pages: 505-507
•
•
•
•
•
Publication
29904909 | J:288801
First Author: Sementino E
Year: 2018
Journal: J Cell Physiol
Title: Inactivation of Tp53 and Pten drives rapid development of pleural and peritoneal malignant mesotheliomas.
Volume: 233
Issue: 11
Pages: 8952-8961
•
•
•
•
•
Publication
22190384 | J:211100
First Author: Antico Arciuch VG
Year: 2011
Journal: Oncotarget
Title: Thyrocyte-specific inactivation of p53 and Pten results in anaplastic thyroid carcinomas faithfully recapitulating human tumors.
Volume: 2
Issue: 12
Pages: 1109-26
•
•
•
•
•
Publication
24444712 | J:211600
First Author: Cho H
Year: 2014
Journal: Cancer Discov
Title: RapidCaP, a novel GEM model for metastatic prostate cancer analysis and therapy, reveals myc as a driver of Pten-mutant metastasis.
Volume: 4
Issue: 3
Pages: 318-33
•
•
•
•
•
Publication
27683179 | J:350188
First Author: Zhang KJ
Year: 2017
Journal: Clin Cancer Res
Title: A Potent In Vivo Antitumor Efficacy of Novel Recombinant Type I Interferon.
Volume: 23
Issue: 8
Pages: 2038-2049
•
•
•
•
•
Publication
19016531 | J:141373
First Author: Henley T
Year: 2008
Journal: Eur J Immunol
Title: B-cell responses to B-cell activation factor of the TNF family (BAFF) are impaired in the absence of PI3K delta.
Volume: 38
Issue: 12
Pages: 3543-8
•
•
•
•
•
Publication
39303726 | J:357411
First Author: Calì B
Year: 2024
Journal: Cancer Cell
Title: Coagulation factor X promotes resistance to androgen-deprivation therapy in prostate cancer.
Volume: 42
Issue: 10
Pages: 1676-1692.e11
•
•
•
•
•
Publication
32788364 | J:295972
First Author: Li Q
Year: 2020
Journal: Proc Natl Acad Sci U S A
Title: Mechanism of PRL2 phosphatase-mediated PTEN degradation and tumorigenesis.
Volume: 117
Issue: 34
Pages: 20538-20548
•
•
•
•
•
Publication
15958561 | J:99385
First Author: Xiao A
Year: 2005
Journal: Cancer Res
Title: Somatic induction of Pten loss in a preclinical astrocytoma model reveals major roles in disease progression and avenues for target discovery and validation.
Volume: 65
Issue: 12
Pages: 5172-80
•
•
•
•
•
Publication
25056937 | J:317519
First Author: Nazarian A
Year: 2014
Journal: Mol Cell Proteomics
Title: Inhibition of circulating dipeptidyl peptidase 4 activity in patients with metastatic prostate cancer.
Volume: 13
Issue: 11
Pages: 3082-96
•
•
•
•
•
Publication
22700876 | J:189280
First Author: Keng VW
Year: 2012
Journal: Cancer Res
Title: PTEN and NF1 inactivation in Schwann cells produces a severe phenotype in the peripheral nervous system that promotes the development and malignant progression of peripheral nerve sheath tumors.
Volume: 72
Issue: 13
Pages: 3405-13
•
•
•
•
•
Publication
30478082 | J:274104
First Author: Li XX
Year: 2019
Journal: G3 (Bethesda)
Title: Conditional Inactivation of Nf1 and Pten in Schwann Cells Results in Abnormal Neuromuscular Junction Maturation.
Volume: 9
Issue: 1
Pages: 297-303
•
•
•
•
•
Publication
29872062 | J:262552
First Author: Cabral-Costa JV
Year: 2018
Journal: Sci Rep
Title: Intermittent fasting uncovers and rescues cognitive phenotypes in PTEN neuronal haploinsufficient mice.
Volume: 8
Issue: 1
Pages: 8595
•
•
•
•
•
Publication
33214645 | J:300231
First Author: de Mello NP
Year: 2020
Journal: Sci Rep
Title: Inverse sex-based expression profiles of PTEN and Klotho in mice.
Volume: 10
Issue: 1
Pages: 20189
•
•
•
•
•
Publication
29453322 | J:260731
First Author: Ding M
Year: 2018
Journal: Mol Cancer Res
Title: The mTOR Targets 4E-BP1/2 Restrain Tumor Growth and Promote Hypoxia Tolerance in PTEN-driven Prostate Cancer.
Volume: 16
Issue: 4
Pages: 682-695
•
•
•
•
•
Publication
23817021 | J:200002
First Author: Chen Y
Year: 2013
Journal: Nat Med
Title: ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss.
Volume: 19
Issue: 8
Pages: 1023-9
•
•
•
•
•
Publication
28292441 | J:239660
First Author: Blattner M
Year: 2017
Journal: Cancer Cell
Title: SPOP Mutation Drives Prostate Tumorigenesis In Vivo through Coordinate Regulation of PI3K/mTOR and AR Signaling.
Volume: 31
Issue: 3
Pages: 436-451
•
•
•
•
•
Publication
27869166 | J:241247
First Author: Lu W
Year: 2017
Journal: Oncogene
Title: SKP2 loss destabilizes EZH2 by promoting TRAF6-mediated ubiquitination to suppress prostate cancer.
Volume: 36
Issue: 10
Pages: 1364-1373
•
•
•
•
•
Publication
32323921 | J:294705
First Author: Oberhuber M
Year: 2020
Journal: Mol Syst Biol
Title: STAT3-dependent analysis reveals PDK4 as independent predictor of recurrence in prostate cancer.
Volume: 16
Issue: 4
Pages: e9247
•
•
•
•
•
Publication
34547241 | J:315701
First Author: Igelmann S
Year: 2021
Journal: Mol Cell
Title: A hydride transfer complex reprograms NAD metabolism and bypasses senescence.
Volume: 81
Issue: 18
Pages: 3848-3865.e19
•
•
•
•
•
Publication
37055829 | J:334748
First Author: Alvarez-Arzola R
Year: 2023
Journal: Cell Commun Signal
Title: VSSP-activated macrophages mediate senescence and tumor inhibition in a preclinical model of advanced prostate cancer.
Volume: 21
Issue: 1
Pages: 76
•
•
•
•
•
Publication
23428429 | J:198151
First Author: Nguyen AH
Year: 2013
Journal: Hum Mol Genet
Title: Gata3 antagonizes cancer progression in Pten-deficient prostates.
Volume: 22
Issue: 12
Pages: 2400-10
•
•
•
•
•
Publication
31452834 | J:315777
First Author: Mohammad AH
Year: 2019
Journal: Oncotarget
Title: V-ATPase-associated prorenin receptor is upregulated in prostate cancer after PTEN loss.
Volume: 10
Issue: 48
Pages: 4923-4936
•
•
•
•
•
Publication
23727861 | J:203214
First Author: Wang G
Year: 2013
Journal: Nat Genet
Title: Zbtb7a suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion.
Volume: 45
Issue: 7
Pages: 739-746
•
•
•
•
•
Publication
23727860 | J:203215
First Author: Lunardi A
Year: 2013
Journal: Nat Genet
Title: A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer.
Volume: 45
Issue: 7
Pages: 747-55
•
•
•
•
•
Publication
34496233 | J:320671
First Author: Grbesa I
Year: 2021
Journal: Cell Rep
Title: Reshaping of the androgen-driven chromatin landscape in normal prostate cells by early cancer drivers and effect on therapeutic sensitivity.
Volume: 36
Issue: 10
Pages: 109625
•
•
•
•
•
Publication
29335542 | J:261541
First Author: Chen J
Year: 2018
Journal: Nat Genet
Title: Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer.
Volume: 50
Issue: 2
Pages: 219-228
•
•
•
•
•
Publication
21394210 | J:171722
First Author: Clegg NJ
Year: 2011
Journal: PLoS One
Title: MYC cooperates with AKT in prostate tumorigenesis and alters sensitivity to mTOR inhibitors.
Volume: 6
Issue: 3
Pages: e17449
•
•
•
•
•




MouseMine is a collaboration between MGI at The Jackson Laboratory and the InterMine project at the Cambridge Systems Biology Centre. MouseMine is funded through a grant from the NIH/NHGRI.The Jackson Laboratory makes no representation about the suitability or accuracy of this software or data for any purpose, and makes no warranties, either express or implied, including merchantability and fitness for a particular purpose or that the use of this software or data will not infringe any third party patents, copyrights, trademarks, or other rights. the software and data are provided "as is". This software and data are provided to enhance knowledge and encourage progress in the scientific community and are to be used only for research and educational purposes. Any reproduction or use for commercial purpose is prohibited without the prior express written permission of the Jackson Laboratory.

Copyright © 2017 by The Jackson Laboratory. All Rights Reserved

© 2002 - 2017 Department of Genetics, University of Cambridge, Downing Street,
Cambridge CB2 3EH, United Kingdom